In summary, the accumulated evidence underscores the clinical promise of 177Lu-PSMA-617 as a highly versatile and tumor-specific radioligand capable of effectively targeting both skeletal and visceral metastases in advanced prostate cancer [45,46,47,48]. This evidence concerns the gene FOLH1 and prostate cancer.